ARTICLE | Company News
ImmunoGen surges on ADC deal with Takeda
March 24, 2015 1:54 AM UTC
ImmunoGen Inc. (NASDAQ:IMGN) gained $1.25 (17%) to $8.69 on Monday on news that Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) licensed exclusive rights to the biotech's antibody-drug conjugate (ADC) technology to develop and commercialize cancer therapies against two undisclosed targets. The companies said the deal includes access to ImmunoGen's cytotoxic DNA-acting IGN payload agents. ...